AGP Executive Report
Last update: 6 hours agoPhage + microbiome trial: A new €15m Horizon Europe project is testing whether CRISPR-enhanced phage therapy, paired with microbiome restoration, can break the cycle of recurrent urinary tract infections—aiming to reduce repeat antibiotics and protect gut health. Latvian research shake-up: Latvia’s Biomedical Research and Study Center and Institute of Organic Synthesis are merging into a new institute to speed drug, diagnostic, and medical technology development from lab to hospitals and industry. Hospital capacity in Latvia: Eurostat data shows Latvia sits mid-pack on hospital beds (497 per 100,000 in 2024), while several EU countries report far lower or higher bed ratios. Recurrent UTI innovation: The phage approach targets persistent E. coli thought to recolonize the urinary tract after symptoms fade. Heat and health risk: Heat waves across Europe are driving demand for cooling, with older people at higher risk from heat-related illness and worsening cardiovascular and respiratory conditions. Cancer tech research: A UK-led project is exploring “magnetobots” using naturally magnetic bacteria to deliver targeted cancer therapies. Local health systems: All Latvian ambulance crews are equipped with body armour and helmets. Public health context: EU population decline from 2029 is expected to strain labour markets and healthcare systems, while also expanding the “longevity economy.” Latvia in global health news: Latvia is among countries backing a European innovation push and participating in major EU-wide initiatives.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
